[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596532":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":42,"collaborators":10,"id":44,"slug":10,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-MY6349 PET\u002FCT",null,"Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET\u002FCT imaging at baseline and following two cycles of Trop2-ADC therapy.",[13],"Diagnostic Test: 68Ga-MY6349 PET\u002FCT",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":10},"DIAGNOSTIC_TEST",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Liang Zhao, phd","CONTACT","86 18818350620","wzhaoliang01@163.com",[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Xiamen","Fujian","361000","China","CN",{"type":33,"coordinates":34},"Point",[35,36],118.08187,24.47979,{"lat":36,"lon":35},[39],{"name":40,"role":21,"phone":41,"phoneExt":10,"email":23},"Liang Zhao","86 0592-213-7366",{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100596532",false,"NCT07046689","PET\u002FCT for Trop2 ADC Response Evaluation Cancers","Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET\u002FCT in Advanced Breast Cancer","Inclusion Criteria:\n\n* adult patients (aged 18 years or order)\n* histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports\n* presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1\n* willingness to undergo serial 68Ga-MY6349 PET\u002FCT scans before and during Trop2-ADC therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* Evidence of significantly impaired hepatic or renal function\n* Estimated life expectancy of less than 3 months","FEMALE","18 Years",{"count":53,"type":54},50,"ESTIMATED","OBSERVATIONAL","To evaluate whether serial 68Ga-MY6349 PET\u002FCT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.",[58,59,60],"Breast Cancer","Trop2","PET\u002FCT",[62,59,60,63],"Breast cancer","Trop2-ADC","2025-07-14",{"date":66,"type":67},"2025-07-15","ACTUAL",{"date":69,"type":67},"2024-11-01",{"date":71,"type":54},"2026-12-31",{"name":5,"class":6},1]